Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,148.6
-11.1 (-0.35%)

 

  • STI Straits Times Index
    3,148.6
    -11.1 (-0.35%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,593.3
    -4.1 (-0.26%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,200.5
    -235.2 (-0.89%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,966.0
    -40.5 (-1.35%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    22,079.1
    34.6 (0.16%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,213.3
    -18.2 (-0.29%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,088.8
    -2.7 (-0.13%)
    Index delayed 20 minutes
  • XAO XAO
    6,867.7
    28.7 (0.42%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 247.1M
  • Value: 309.7M
  • Rise: 82
  • Fall: 128
  • Unch: 626

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Rex Intl0.083-0.001
JCG Investment0.002-
YZJ Shipbldg SGD1.020+0.020
Nam Cheong0.006-0.002
Keppel DC Reit1.980-0.130
SingPost0.965+0.020
Genting Sing0.895-0.010
Golden Agri-Res0.240-0.005
ZICO Hldgs0.133-
SingTel3.170-

World Indices

World Indices
Name Last Change
Nasdaq 8,117.7 -65.2
HSI 26,215.8 -219.9
HSCEI 10,291.1 -84.6
Jakarta 6,213.3 -18.2
Nikkei 225 22,079.1 +34.6
SSE Comp 2,964.0 -42.4
Shanghai A 3,105.1 -44.5
Shanghai B 272.5 -0.9
PSE Comp 0.0
KOSPI 2,090.5 -1.0

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Lonza LONZA GROUP LTD
Quotes 10 Minutes Delayed. Updated at 23 Sep 2019 07:12
Last (SGD): 79.970 Change: - High: - Remarks: -
Change (%): - Low: -
Open - Yesterday's Close 79.970
Buy Price - Sell Price -
Buy Volume ('000) - Sell Volume ('000) -
Cumulative Volume ('000) - Cumulative Value -
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 10.43523 Trailing EPS (SGD) e 8.57097 NAV (SGD) b 115.3124
PE a 7.663 Trailing PE f 9.330 Price / NAV b 0.6935
Dividend (SGD) d 3.811500 Cash In Hand (SGD) g 7.7136 Issued & Paid-up Shares c 74,246,000
Dividend Yield (%) d 4.766 Price / Cash In Hand g 10.367 Treasury Shares h 223,000
Beta - 75 Daysi - R-Squared - 75 Days(%)i - Market Cap (M) 5,937.453
Beta - 500 Daysi - R-Squared - 500 Days (%)i - Enterprise Value (M) 10,711.861
Piotroski F Score 7 Exchange Code O6Z Par Value ( CHF ) 1.00000
52 Weeks Volatility (%) 0.0 6-Month VWAP n.a. Free Float (%) 99.8
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Manufacturing - Biotechnology
Category Classification Foreign Listing (Others) / Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 08 Mar 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 08 Mar 2019.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Lonza SGX 5,937.453 7.663 9.330 0.6935 4.766
Industry Biotechnology SGX 1,987.558 7.340 9.734 0.6937 4.746
Foreign Listing (Others) SGX 6,733.146 14.160 14.518 1.5050 3.460
Medical & Biotechnology SGX 1,021.102 23.219 26.451 1.4266 1.827
Local Peer Suntar Eco-City^ SGX 18.514 - - 1.1170 -
Local Peer QT Vascular SGX 6.706 0.167 - 0.3947 -
Global Peer AMGEN INC NASDAQ 118,105.115 14.070 14.841 10.9417 2.815
Global Peer GILEAD SCIENCES INC NASDAQ 84,117.609 15.420 14.126 3.7194 3.475
Global Peer AMGEN-T HKEx 599,701.000 9.116 9.612 7.1115 4.345
Global Peer CSL ASX 106,428.763 39.669 39.669 14.2225 1.132
Global Peer CELGENE CORP NASDAQ 70,427.593 17.407 13.361 7.0070 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 45,783.074 21.839 20.670 9.0303 -
Global Peer ILLUMINA INC NASDAQ 45,506.790 55.093 48.515 10.5048 -
Global Peer BIOGEN INC NASDAQ 44,044.099 9.941 8.319 3.4003 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,514.441 13.302 15.713 3.3328 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 24,129.220 76.358 22.509 5.0831 0.785
Other Global Peers ALEXION PHARMACEUTICAL INC (NASDAQ), INCYTE CORPORATION (NASDAQ), SINO BIOPHARM (HKEx), EXACT SCIENCES CORP (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), WUXI BIO (HKEx), SEATTLE GENETICS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BEIGENE (HKEx), BIO-TECHNE CORP (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), MODERNA INC (NASDAQ), EXELIXIS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), REPLIGEN CORP (NASDAQ), GENSCRIPT BIO (HKEx), 3SBIO (HKEx), ALLOGENE THERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), FIBROGEN INC (NASDAQ), ALKERMES PLC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), NATERA INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), ACCELERON PHARMA (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), XENCOR INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), INSMED INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), REGENXBIO INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), ALECTOR INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), VERACYTE INC (NASDAQ), OPKO HEALTH INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), 10X GENOMICS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), FRONTAGE (HKEx), CARA THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), EPIZYME INC (NASDAQ), POLYNOVO LIMITED (ASX), DICERNA PHARMACEUTICALS INC. (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), VIVA BIOTECH (HKEx), SPECTRUM PHARMACEUTICALS INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), OMEROS CORP (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), NEXTCURE INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), ARVINAS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), AVITA MEDICAL LTD (ASX), CYTOKINETICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), HAOHAI BIOTEC (HKEx), UROGEN PHARMA LTD (NASDAQ), CORTEXYME INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), VOYAGER THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), MACROGENICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), SYNTHORX INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), TG THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), RETROPHIN INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), AKEBIA THERAPEUTICS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), ASCLETIS-B (HKEx), ACHILLION PHARMACEUTICALS INC (NASDAQ), PERSONALIS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), MERUS B V (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), DERMIRA INC (NASDAQ), CKLIFE SCIENCES (HKEx), CHEMOCENTRYX INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), AGENUS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), XBIOTECH INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), ESSEX BIO-TECH (HKEx), LEXICON PHARMACEUTICALS INC (NASDAQ), KADMON HLDGS INC (NYSE), PROTAGONIST THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), NEXT SCIENCE LTD (ASX), RESTORBIO INC (NASDAQ), LEE'S PHARM (HKEx), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), MEDICINOVA INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), ARDELYX INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), PIERIS PHARMACEUTICALS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), COMPUGEN (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), GERON CORP (NASDAQ), RECRO PHARMA INC (NASDAQ), TELIX PHARMACEUTIC (ASX), CLOVIS ONCOLOGY INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), PDL BIOPHARMA INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), XENON PHARMACEUTICALS INC (NASDAQ), CHIASMA INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), DPHARMA (Bursa), ATHERSYS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), AFFIMED N V (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), KAMADA (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), PFENEX INC (NYSE American), CUE BIOPHARMA INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), GLYCOMIMETICS INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), XOMA CORP (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), BICYCLE THERAPEUTICS LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ENZO BIOCHEM INC (NYSE), IMV INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), AVEO PHARMACEUTICALS INC (NASDAQ), NOVAVAX INC (NASDAQ), UNI-BIO GROUP (HKEx), BBI LIFE SCI (HKEx), CHIMERIX INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), HARVARD BIOSCIENCE INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), NANTKWEST INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), SESEN BIO INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), VACCINEX INC (NASDAQ), SAVARA INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), VERASTEM INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), ADURO BIOTECH INC (NASDAQ), ARAVIVE INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), ARBUTUS BIOPHARMA CORP (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), TREVENA INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), SYNLOGIC INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), CURIS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), CEL-SCI CORP (NYSE American), MERRIMACK PHARMACEUTICALS INC (NASDAQ), PHYLOGICA LIMITED (ASX), INFLARX N V (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ORGENESIS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), OTONOMY INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), EQUILLIUM INC (NASDAQ), PORT (SET), NEON THERAPEUTICS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), INMUNE BIO INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), COHBAR INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), IMMUTEP LTD (ASX), IMUGENE LIMITED (ASX), IBIO INC (NYSE American), UNUM THERAPEUTICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), VERMILLION INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), CT ENTERPRISE (HKEx), CIDARA THERAPEUTICS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 2 ORD SHS (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), IVERIC BIO INC (NASDAQ), EVOGENE LTD (NASDAQ), REGENT PACIFIC (HKEx), ARMATA PHARMACEUTICALS INC (NYSE American), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), ORTHOCELL LIMITED (ASX), CELLDEX THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), BIOCARDIA INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), ZAFGEN INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), FIBROCELL SCIENCE INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), SENESTECH INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), BIOTRON (ASX), EXTRAWELL PHAR (HKEx), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), BIOSINO BIO-TEC (HKEx), AZURRX BIOPHARMA INC (NASDAQ), ORAGENICS INC (NYSE American), RHINOMED LIMITED (ASX), CELLECTAR BIOSCIENCES INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), HISTOGENICS CORP (NASDAQ), MEMPHASYS LTD (ASX), BIOCEPT INC (NASDAQ), ISORAY INC (NYSE American), SOLIGENIX INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), ACTINIUM PHARMACEUTICALS INC (NYSE American), NOVELION THERAPEUTICS INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), TOCAGEN INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), BIONOMICS LTD (ASX), ONCOLYTICS BIOTECH INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), PULMATRIX INCORPORATED (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), PATRYS LIMITED (ASX), ADALTA LTD (ASX), ATYR PHARMA INC (NASDAQ), PRECIPIO INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), REGENEUS LTD (ASX), DARE BIOSCIENCE INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), IMMURON LIMITED (ASX), ANTEO DIAGNOSTICS LIMITED (ASX), CELLMID LIMITED (ASX), CLEVELAND BIOLABS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), NANOVIRICIDES INC (NYSE American), ENDRA LIFE SCIENCES INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), GENETIC TECHNOLOGIES (ASX), TROVAGENE INC (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), BIOXYNE LIMITED (ASX), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), HAO WEN HLDGS (HKEx), REXAHN PHARMACEUTICALS INC (NASDAQ), VAXART INC (NASDAQ), BENITEC BIOPHARMA LTD (ASX), BIONANO GENOMICS INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), MEDIBIO LIMITED (ASX), ANATARA LIFESCIENCES LTD (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ADVAXIS INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), LIVING CELL TECHNOLOGIES (ASX), AURIS MEDICAL HOLDING LTD (NASDAQ), MGRC (Bursa), PLUS THERAPEUTICS INC (NASDAQ), MEGASUN (Bursa), OPGEN INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), NOVITA HEALTHCARE LTD (ASX), SPHERIX INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), TBG DIAGNOSTICS LTD (ASX), CCP TECHNOLOGIES LTD (ASX), NEURALSTEM INC (NASDAQ), NANOLLOSE LTD (ASX), BPH ENERGY LIMITED (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), ALCHEMIA LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

Not enough data to show total shareholder returns
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 79.970 - 79.970 Change From 1 Year Low - % Change From 1 Year Low (%) -
Change From 1 Year High - % Change From 1 Year High (%) -
2 Years Range 79.970 - 79.970 Change From 2 Years Low - % Change From 2 Years Low (%) -
Change From 2 Years High - % Change From 2 Years High (%) -
5 Years Range 79.970 - 79.970 Change From 5 Years Low - % Change From 5 Years Low (%) -
Change From 5 Years High - % Change From 5 Years High (%) -
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Lonza Group Ltd is a corporation incorporated under the laws of Switzerland and has been listed on the SIX Swiss Exchange (the “SIX”) since November 1999.Lonza is a supplier to the pharmaceutical, healthcare and life sciences industries with products and services spanning from research to final product manufacture to meet customers' needs. The products Lonza manufacture for the life sciences industry can be characterised as very complex molecules which are manufactured in a highly regulated environment and will end up in the body of human beings or animals.Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. The Group has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. The Group provides cell-based research, endotoxin detection and cell therapy manufacturing. The Group is also a provider of high value chemicals and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.To provide optimal support to its customers, the Group is organized into three business divisions, namely, Custom Manufacturing, Life Science Ingredients and Bioscience, which focus on specific sets of customers and their needs.

IPO Performance

Listing Date 21 Oct 2011 Full Subscription Rate (x) -
No of Placement Shares (M) - No of Public Offer Shares (M) - Public Offer Subscription Rate (x) -
IPO Price (SGD) a - First Day Close (SGD) a 79.970 First Week Close (SGD) a 79.970
Current vs IPO Price (%) - First Day Gain (%) - First Week Gain (%) -
Notes:
  1. Adjusted for the following: IPO Price is not available as there are no issue of Shares under the Listing by way of Introduction.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2018 Dec 2018 Part 1(3.19 MB)
Part 2(7.67 MB)
Annual Report 2017 Dec 2017 Part 1(10.98 MB)
Annual Report 2016 Dec 2016 Part 1(7.93 MB)
Annual Report 2015 Dec 2015 Part 1(1.90 MB)
Part 2(2.28 MB)
Annual Report 2014 Dec 2014 Part 1(3.90 MB)
Part 2(6.06 MB)
Annual Report 2013 Dec 2013 Part 1(3.42 MB)
Annual Report 2012 Dec 2012 Part 1(3.87 MB)
Annual Report 2011 Dec 2011 Part 1(5.01 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
20 Sep 2019 79.970 79.970 79.970 79.970 - -
19 Sep 2019 79.970 79.970 79.970 79.970 - -
18 Sep 2019 79.970 79.970 79.970 79.970 - -
17 Sep 2019 79.970 79.970 79.970 79.970 - -
16 Sep 2019 79.970 79.970 79.970 79.970 - -
13 Sep 2019 79.970 79.970 79.970 79.970 - -
12 Sep 2019 79.970 79.970 79.970 79.970 - -
11 Sep 2019 79.970 79.970 79.970 79.970 - -
10 Sep 2019 79.970 79.970 79.970 79.970 - -
09 Sep 2019 79.970 79.970 79.970 79.970 - -
06 Sep 2019 79.970 79.970 79.970 79.970 - -
05 Sep 2019 79.970 79.970 79.970 79.970 - -
04 Sep 2019 79.970 79.970 79.970 79.970 - -
03 Sep 2019 79.970 79.970 79.970 79.970 - -
02 Sep 2019 79.970 79.970 79.970 79.970 - -
30 Aug 2019 79.970 79.970 79.970 79.970 - -
29 Aug 2019 79.970 79.970 79.970 79.970 - -
28 Aug 2019 79.970 79.970 79.970 79.970 - -
27 Aug 2019 79.970 79.970 79.970 79.970 - -
26 Aug 2019 79.970 79.970 79.970 79.970 - -
23 Aug 2019 79.970 79.970 79.970 79.970 - -
22 Aug 2019 79.970 79.970 79.970 79.970 - -
Summary
Current 2 Weeks
(09 Sep 2019 to 20 Sep 2019)
79.970 79.970 79.970 79.970 - -
Previous 2 Weeks
(26 Aug 2019 to 06 Sep 2019)
79.970 79.970 79.970 79.970 - -
4 Weeks from
(25 Jul 2019 to 23 Aug 2019)
79.970 79.970 79.970 79.970 - -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.